Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Paysign, Inc. (PAYS)
NASDAQInformation TechnologySpecialty Business ServicesSnapshot 2026-11-04
$14.32-6.41%
Close 2026-11-05 · 1-day change
NASDAQInformation TechnologySpecialty Business ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.42 → 0.42 EPS · FY ending Dec 31, 2027 · 2 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 2; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for PAYS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Gross profit rises to about $18.2M in 2026-Q1 | Profit margins expand, with gross profit rising from $13.1M to $18.2M in recent quarters. | Intact | Gross profit falls below $15M in next 4 quarters | Gross profit: $17.897M FY2026-Q2; GAAP. Published target: ~$18.2M. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 202617,897,023 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth-oriented business with improving earnings quality, rather than a turnaround. Its long-term thesis remains intact, with management on track against stated priorities, but the signal has shifted from mildly favorable to mixed.
PAYS is expensive versus peers, with a 1.14 premium measure, and the expectations gap is negative, suggesting expectations are demanding relative to the evidence. The priced-in assessment is justified, with low fragility, but valuation has weakened and the evidence does not point to a wide cushion for disappointment.
In the latest year-over-year quarter, pharma and plasma revenue grew, gross margin improved, and operating margin expanded; net income also rose sharply. Management's priorities remain on track, though near-term earnings risk is meaningful: PAYS recently missed, and the snapshot flags a run of misses across the company and its peers.
The multi-year case depends on continued growth in both pharma and plasma revenue, margin gains, and progress toward management's net income goal. Near term, a guidance reversal after the recent raise would damage credibility, while rate cuts or steadier results from sector peers could ease pressure on the Tech backdrop.
For the next 1 to 3 years, PAYS combines real operating progress with a demanding valuation and high near-term execution risk. The long-term thesis remains intact, but it hinges on sustaining growth and margins without another guidance setback. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “Exhibit 99.1 Earnings Release Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook Growth Driven by Continued Momentum in Plasma and Patient Affordability Businesses Mix Shift and Expense Discipline Continue to Drive Gross and Operating Margin Expansion Balance Sheet Supports Continued Investment and Growth Initiatives HENDERSON, Nev.” “Exhibit 99.1 Earnings Release Paysign’s Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026 Mix Shift Continues to Deliver Expansion in Gross and Operating Margin Strong Balance Sheet Enables Continued Investment for Profitable Growth HENDERSON, Nev.”
Net income doubles to about $5.4M in 2026-Q1 | Net income doubled from $1.4M to $5.4M, showing strong profit growth. | Intact | Net income falls below $3M in next 4 quarters | Net income: $6.757M FY2026-Q2; GAAP. Published target: ~$5.4M. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 20266,756,537 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Revenue, operating margin and net income all finished above the high end of our guidance, and the strength we’ve seen through the first half of the year, combined with the visibility into additional program launches and seasonal trends, supports our increased full-year outlook.”” ““Revenue, operating margin and net income all finished above the high end of our prior ranges, driven by fixed cost leverage and a continued mix shift toward patient affordability.” Delivery assessment Nov 3, 2026 |
Revenue grows to about $108.5M in FY26 | Paysign grows revenue about 23% yearly to $108.5M in 2026. | Intact | Revenue falls below $100M in FY26 | Revenue: $28.252M FY2026-Q2; GAAP. Published target: ~$108.5M. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 202628,252,071 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Exhibit 99.1 Earnings Release Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook Growth Driven by Continued Momentum in Plasma and Patient Affordability Businesses Mix Shift and Expense Discipline Continue to Drive Gross and Operating Margin Expansion Balance Sheet Supports Continued Investment and Growth Initiatives HENDERSON, Nev.” “Exhibit 99.1 Earnings Release Paysign’s Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026 Mix Shift Continues to Deliver Expansion in Gross and Operating Margin Strong Balance Sheet Enables Continued Investment for Profitable Growth HENDERSON, Nev.” Revenue was $28.038 million in 2026-Q1. Delivery assessment Nov 3, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.31 → $0.42 · observed estimates
$0.13B → $0.13B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.31 | $125,019,800 | 2 / 3 |
| 2026-07-25 | $0.44 | $125,019,800 | 3 / 5 |
| 2026-07-26 | $0.44 | $125,019,800 | 3 / 5 |
| 2026-07-27 | $0.44 | $125,019,800 | 3 / 5 |
| 2026-07-28 | $0.44 | $125,019,800 | 3 / 5 |
| 2026-07-29 | $0.31 | $125,019,800 | 2 / 3 |
| 2026-07-30 | $0.31 | $125,019,800 | 2 / 3 |
| 2026-07-31 | $0.44 | $125,019,800 | 3 / 5 |
| 2026-08-01 | $0.31 | $125,019,800 | 2 / 3 |
| 2026-08-02 | $0.44 | $125,019,800 | 3 / 5 |
| 2026-08-03 | $0.31 | $125,019,800 | 2 / 3 |
| 2026-08-04 | $0.31 | $125,019,800 | 2 / 3 |
| 2026-08-05 | $0.44 | $125,019,800 | 3 / 5 |
| 2026-08-06 | $0.31 | $125,019,800 | 2 / 3 |
| 2026-08-07 | $0.38 | $130,238,098 | 2 / 3 |
| 2026-08-08 | $0.60 | $132,558,000 | 2 / 5 |
| 2026-08-09 | $0.60 | $132,558,000 | 2 / 5 |
| 2026-08-10 | $0.60 | $132,558,000 | 2 / 5 |
| 2026-08-12 | $0.38 | $130,238,098 | 2 / 3 |
| 2026-08-13 | $0.38 | $130,238,098 | 2 / 3 |
| 2026-08-14 | $0.38 | $130,238,098 | 2 / 3 |
| 2026-08-15 | $0.38 | $130,238,098 | 2 / 3 |
| 2026-08-16 | $0.38 | $130,238,098 | 2 / 3 |
| 2026-08-17 | $0.38 | $130,238,098 | 2 / 3 |
| 2026-08-18 | $0.38 | $130,238,098 | 2 / 3 |
| 2026-08-19 | $0.38 | $130,238,098 | 2 / 3 |
| 2026-08-20 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-08-21 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-08-22 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-08-23 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-08-24 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-08-25 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-08-26 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-08-27 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-08-28 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-08-29 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-08-30 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-08-31 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-01 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-02 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-03 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-04 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-05 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-06 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-07 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-08 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-09 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-10 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-11 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-12 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-13 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-14 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-15 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-16 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-17 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-18 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-19 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-20 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-21 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-22 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-23 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-24 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-25 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-26 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-27 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-28 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-29 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-09-30 | $0.42 | $133,220,200 | 2 / 3 |
| 2026-10-01 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-02 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-03 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-04 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-05 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-06 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-07 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-08 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-09 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-10 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-11 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-12 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-13 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-14 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-15 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-16 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-17 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-18 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-19 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-20 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-21 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-22 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-23 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-24 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-25 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-26 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-27 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-28 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-29 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-30 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-10-31 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-11-01 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-11-02 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-11-03 | $0.42 | $133,650,399 | 2 / 3 |
| 2026-11-04 | $0.42 | $133,650,399 | 2 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.